The evolution of drugs on schistosoma treatment: Looking to the past to improve the future

Mini-Reviews in Medicinal Chemistry

Volumn 13, Issue 4, 2013, Pages 493-508

  Pitta, Maira Galdino da Rocha ^a   Pitta, Marina Galdino da Rocha ^a   Rêgo, Moacyr Jesus Barreto de Melo ^a   Galdino, Suely Lins ^a  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

Author keywords

Anti schistosoma therapies; Chemical structure of compounds; Parasitic disease; Resistance to treatment; Schistosomiasis

Indexed keywords

1 (5 NITRO 2 THIAZOLYL) 2 IMIDAZOLIDINEDIONE; 1 [(3 METHOXYPHENYL)METHYL] 2 [2 (5 NITRO 2 FURANYL)ETHENYL] 1H IMIDAZOLE; 1 [2 (DIETHYLAMINO)ETHYL]AMINO] 4 (HYDROXYMETHYL) 9H THIOXANTHEN 9 ONE; 1 [2 (DIETHYLAMINO)ETHYL]AMINO] 4 METHYL 9H XANTHEN 9 OL; 1 ETHYL 3 (3 BENZYL 5 NITRO 4 THIAZOLINE 2 YLIDENE) UREA; 1,2,3,3A,4,5 HEXAHYDRO 2(1METHYLETHYL) 8 NITRO IMIDAZO[1,5 A]QUINOLINE 7 METHANOL; 1,2,3,4 TETRAHYDRO 2 [(1 METHYLETHYL)AMINO]METHYL] 7 NITRO 6 QUINOLINEMETHANOL; 1,2,3,4 TETRAHYDRO 6 METHYL N (1 METHYLETHYL) 7 NITRO 2 QUINOLINEMETHANAMINE; 2 [(5 NITRO 2 FURANYL)METHYLENE] HYDRAZINECARBOTHIOAMIDE; 3 (4 CHLORO BENZYL) 2 METHYLENE 5 (4 NITROBENZYLIDENE) IMIDAZOLIDIN 4 ONE; 3 (4 CHLORO BENZYL) 5 (4 FLUOROBENZYLIDENE) 1 METHYL 2 THIOXOIMIDAZOLIDIN 4 ONE; 3 [(4 CHLOROPHENYL)METHYL] 5 [(4 NITROPHENYL)METHYLENE] 2,4 IMIDAZOLIDINEDIONE; 4 [2 (DIETHYLAMINO)ETHYL]AMINO] 1 METHYL 9H XANTHEN 9 ONE; 4,5 DIHYDRO 2 METHYLTHIO) 1 (5 NITRO 2 FURANYL) 1H IMIDAZOLE; 5 (2,4,5 TRICLHOROPHENYL) 2,4 IMIDAZOLIDINEDIONE; 5 NITRO 2 FURANYL DERIVATIVE; 5 NITRO 2 THIAZOLYL; 8 CHLORO 2 [2 (DIETHYLAMINO)ETHYL] 2H [1]BENZOTHIOPYRANO[4,3,2 CD] INDAZOLE 5 METHANOL; 8 CHLORO 4 [(2 DIETHYLAMINO) ETHYL]AMINO] 1 METHYL 9H XANTHEN 9 ONE; ANTIMONY GLUCONATE; ANTIMONY TARTRATE; ANTITREMATODAL AGENT; DIHYCON; FUADINE; FURAPROMIDIUM; HYCANTHONE; HYDRATE (1 3 9) SODIUM SALT 2,4 2?,4? O (OXYDUSTIBYLIDYNE)BIS D GLUCONOIC ACID; LUCANTHONE; MIRACIL A; MIRACIL B; MIRACIL C; N (1 METHYLETHYL) 3 (5 NITRO 2 FURANYL) 2 PROPENAMIDE; N (3 ETHYL 5 NITRO 2 (3H) THIAZOLYLIDENE) UREA; N (4 METHOXY 2 METHYLPHENYL) 3 (5 NITRO 2 FURANYL) 2 PROPENAMIDE; NIRIDAZOLE; OXAMNIQUINE; PHENYTOIN; PRAZIQUANTEL; SODIUM SALT (1 6) 2,2' [(1,2 DICARBOXY 1,2 ETHANEDIYL)BIS(THIO)]BIS 1,3,2 DITHIASTIBOLANE 4,5 DICARBOXYLIC ACID; STIBNAL; STIBOCAPTATE; STIBOGLUCONATE SODIUM; STIBOPHEN; THIOSEMICARBAZIDE DERIVATIVE; UK 4261; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANAPHYLAXIS; CHEMOTHERAPY; CLINICAL MEDICINE; CLINICAL TRIAL (TOPIC); DRUG DESIGN; HUMAN; NONHUMAN; PATENT; PUBLIC HEALTH; REVIEW; SCHISTOSOMA; SCHISTOSOMIASIS; SINGLE DRUG DOSE; SOCIOECONOMICS; TROPICAL DISEASE; VACCINATION;

ANIMALS; ANTHELMINTICS; ANTIGENS; DRUG DESIGN; HUMANS; ORGANOPHOSPHATES; PEPTIDE HYDROLASES; PEROXIREDOXINS; PRAZIQUANTEL; SCHISTOSOMA; SCHISTOSOMIASIS;

EID: 84875329666     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557511313040003     Document Type: Review

References (115)

1. WHO http://www.who.int/topics/schistosomiasis/en/. Accessed on 01/12/2012.
2. Wu, W.; Wang, W.; Huang, Y. X., New insight into praziquantel against various developmental stages of schistosomes. Parasitol Res 2011, 109 (6), 1501-7.
3. King, C. H.; Olbrych, S. K.; Soon, M.; Singer, M. E.; Carter, J.; Colley, D. G., Utility of repeated praziquantel dosing in the treatment of schistosomiasis in high-risk communities in Africa: a systematic review. PLoS Negl Trop Dis 2011, 5 (9), e1321.
4. King, C. H.; Dickman, K.; Tisch, D. J., Reassessment of the cost of chronic helminthic infection: a meta-analysis of disabilityrelated outcomes in endemic schistosomiasis. Lancet 2005, 365, 1561-1569.
5. Ross, A. G.; Bartley, P. B.; Sleigh, A. C.; Olds, G. R.; Li, Y.; Williams, G. M.; McManus, D. P., Schistosomiasis. N. Engl. J. Med 2002, 346, 1212-1220.
6. Geoffrey, N. G., Applications for profiling the schistosome transcriptome. Trends in Parasitology 2010, 26, 434-439.
7. J. P, L., Farmacodinâmica. Editora Arte Médica: São Paulo, 1973.
8. Luttermoser, G. W., Dewitt, W.B., Enhancement of Stibophen (Fuadin®) Activity against Schistosoma Mansoni in Mice by Feeding Purified Semi-Synthetic Diets. Am J Trop Med Hyg 1961, 10 (4), 541-546.
9. Farid, Z.; Bassily, S.; Kent, D. C.; Hassan, A.; Abdel-Wahab, M. F.; Wissa, J., Urinary schistosomiasis treated with sodium antimony tartrate--a quantitative evaluation. Br Med J 1968, 3 (5620), 713-4.
10. Rodriguez-Molina, R.; Acevedo, C. E.; Torres, J. M.; Lopez-Sanabria, U.; Ramirez-Rodriguez, E., Treatment of schistosomiasis mansoni with antimony lithium thiomalate (Anthiomaline); final report. Am J Trop Med Hyg 1950, 30 (6), 881-6.
11. Omar, H., Treatment of schistosomiasis in recruits with triostam. Med J Egypt Armed Forces 1956, 2 (2), 30-8.
12. Baruffa, G., Ambulant treatment of urinary schistosomiasis with Astiban (TWSb/6). Trans R Soc Trop Med Hyg 1962, 56, 143-8.
13. Mousa, A. H.; Shoeb, H. A., Synthetic schistosomicides antimonyl benzothiazole derivatives. II. J Egypt Med Assoc 1971, 54 (7), 401-9.
14. Ghaleb, H. A.; Shoeb, H. A.; el-Gawhary, N.; el-Borolossy, A. W.; el-Halawany, S. A.; Madkour, M. K., Influence of the substituent radicals in antimonyl naphthalein derivatives on the potentialities of anti-schistosomal activity in mice. J Egypt Med Assoc 1979, 62 (1-2), 31-43.
15. Marsden, Pentavalent antimonials: old drugs for new diseases. Rev Soc bras Med Trop 1985, 18, 187-198.
16. Cioli, D.; Pica-Mattoccia, L.; Archer, S., Antischistosomal drugs: past, present and future? Pharmacol Ther 1995, 68 (1), 35-85.
17. Blanc, F.; Nosny, Y., [Treatment of schistosomiasis with injections of 2-dehydro-emetine]. Presse Med 1968, 76 (28), 1419-20.
18. Finkbeiner, H., The carboxilation of Hydantoins. J. Org. Chem 1965, 30 (10), 5.
19. Oliveira, S. M., Silva, J.B.P., Hernandes, M.Z., Lima, M.C.A.L., Galdino, S.L., Pitta, I. R, Estrutura, Reatividade e Propriedades Biológicas de Hidantoínas. Quim Nova 2008, 31 (3), 614-622.
20. Werbel, L. M.; Elslager, E. F.; Islip, P. J.; Closier, M. D., Antischistosomal effects of 5-(2,4,5-trichlorophenyl)hydantoin and related compounds. J Med Chem 1977, 20 (12), 1569-72.
21. Lambert, C. R., Chemotherapy of Experimental Schistosoma Mansoni Infections with a Nitro-Thiazole Derivative, Ciba 32,644-Ba. Ann Trop Med Parasitol 1964, 58, 292-303.
22. Fontanilles, F., Risks versus benefits in antischistosomal therapy. Ann N Y Acad Sci 1969, 160 (2), 811-20.
23. Urman, H. K.; Bulay, O.; Clayson, D. B.; Shubik, P., Carcinogenic effects of niridazole. Cancer Lett 1975, 1 (2), 69-74.
24. Legator, M. S.; Connor, T. H.; Stoeckel, M., Detection of mutagenic activity of metronidazole and niridazole in body fluids of humans and mice. Science 1975, 188 (4193), 1118-9.
25. Ong, T. M., Genetic activities of hycanthone and some other antischistosomal drugs. Mutat Res 1978, 55 (1), 43-70.
26. Fantel, A. G.; Greenaway, J. C.; Walker, E.; Juchau, M. R., The toxicity of niridazole in rat embryos in vitro. Teratology 1986, 33 (1), 105-12.
27. Mahmoud, A. A.; Warren, K. S., Anti-inflammatory effects of tartar emetic and niridazole: suppression of schistosome egg granuloma. J Immunol 1974, 112 (1), 222-8.
28. Mahmoud, A. A.; Mandel, A.; Warren, K.; Webster, L. T., Jr., Niridazole. II. A potent long-acting suppressant of cellular hypersensitivity. J Immunol 1975, 114 (1 Pt 2), 279-83.
29. Webster, L. T., Jr.; Butterworth, A. E.; Mahmoud, A. A.; Mngola, E. N.; Warren, K. S., Suppression of delayed hypersensitivity in schistosome-infected patients by niridazole. N Engl J Med 1975, 292 (22), 1144-7.
30. Blumer, J. L.; Simpson, J. M.; Lucas, S. V.; Webster, L. T., Jr., Toxicogenetics of niridazole in inbred mice. J Pharmacol Exp Ther 1980, 212 (3), 509-13.
31. Tracy, J. W.; Fairchild, E. H.; Lucas, S. V.; Webster, L. T., Jr., Isolation, characterization, and synthesis of an immunoregulatory metabolite of niridazole: 1-thiocarbamoyl-2-imidazolidinone. Mol Pharmacol 1980, 18 (2), 313-9.
32. Werbel, L. M.; Degnan, M. B.; Harger, G. F.; Capps, D. B., 1-Alkyl-3-(3-alkyl-5-nitro-4-thiazolin-2-ylidene)ureas and related compounds as schistosomicides. J Med Chem 1972, 15 (9), 955-63.
33. Benazet, F.; Leroy, J. P., [Action of the (nitro-5 thiazolyl-2)-1 imidazolidine thione-2 (26354 R.P.) on experimental bilharziasis in laboratory animals]. Bull Soc Pathol Exot Filiales 1974, 67 (3), 287-97.
34. Ma, Z.; Si, B. X.; Liu, Y. L.; Huang, L. S., [Synthesis of acylates of niridazole and its analogs as schistosomicides]. Yao Xue Xue Bao 1989, 24 (6), 476-80.
35. Oliveira, S. M., Albuquerque, M.C.P.A., Pitta, M.G.R., Malagueño, E., Santana, J.V., Lima, M.C.A., Pitta, I.R., Galdino, L. S, A resposta do Schistosoma mansoni mantido in vitro frente a derivados imidazolidinônicos. Acta Farm Bonaerense 2004, 23 (3), 343-349.
36. Albuquerque, M. C.; Silva, T. G.; Pitta, M. G.; Silva, A. C.; Silva, P. G.; Malagueno, E.; Santana, J. V.; Wanderley, A. G.; Lima, M. C.; Galdino, S. L.; Barbe, J.; Pitta, I. R., Synthesis and schistosomicidal activity of new substituted thioxo-imidazolidine compounds. Pharmazie 2005, 60 (1), 13-7.
37. Pitta, M. G.; Silva, A. C.; Neves, J. K.; Silva, P. G.; Irmao, J. I.; Malagueno, E.; Santana, J. V.; Lima, M. C.; Galdino, S. L.; Pitta, I. R.; Albuquerque, M. C., New imidazolidinic bioisosters: potential candidates for antischistosomal drugs. Mem Inst Oswaldo Cruz 2006, 101 Suppl 1, 313-6.
38. Lorenz, W., Henglein, A and Schrader, G, The new insecticide o, odimethyl-2,2,2-trichloro-l-hydroxyethylphosphonate. J Am Chem Sot 1955, 77.
39. Cerf, J.; Lebrun, A.; Dierichx, J., A new approach to helminthiasis control: the use of an organophosphorous compound. Am J Trop Med Hyg 1962, 11, 514-7.
40. Nordgren. I.; Holmstedt, B.; Bengtsson, E.; Finkel Y., Plasma levels of metrifonate and dichlorvos during treatment of schistosomiasis with bilarcil. Am J Trop Med Hyg 1980; 29, 426-30.
41. Zheng, X. Y.; Chen, C.; Qian, Y. F.; Gan, P. Z.; Jin, X. L.; Xiao, S. H.; Shao, B. R., [a Preliminary Note on the Relationship between Structure and Antischistosomal Activity of Nitrofurazones]. Yao Xue Xue Bao 1963, 10, 407-17.
42. Lei, H. H.; Chang, L. C.; Hsue, M. L.; Chang, S. P.; Tzin, K. C.; Yen, M., A New Class of Chemotherapeutic Agents Orally Effective against Schistosomiasis Japonica. Sci Sin 1964, 13, 523-4.
43. Hill, J.; Rust, M. A.; Pellegrino, J.; Faria, J., Use of the oogram to reveal the effect of a nitrofurylacrylamide on the eggs of Schistosoma mansoni. J Parasitol 1966, 52 (4), 822.
44. Robinson, C. H.; Bueding, E.; Fisher, J., Relationship between structure, conformation, and antischistosomal activity of nitroheterocyclic compounds. Mol Pharmacol 1970, 6 (6), 604-16.
45. Lin, Y.; Hulbert, P. B.; Bueding, E.; Robinson, C. H., Structure and antischistosomal activity in the nitrofurylvinyl and the niridazole series. Noninterchangeability of the nitroheterocyclic rings. J Med Chem 1974, 17 (8), 835-40.
46. Henry, D. W., Cory, M. N-Substituted 2-[2-(5-nitro-2-furyl)vinyl]imidazoles. 1976.
47. Rossignol, J. F., 5-Nitro-2-furanyl derivative and its use as an antiparasitic agent. Eur Pat Appl 1985, 13.
48. Bueding, E.; Naquira, C.; Bouwman, S.; Rose, G., The antischistosomal activity of a nitrovinylfuran derivative (SQ 18,506) in mice and hamsters. J Pharmacol Exp Ther 1971, 178 (2), 402-10.
49. Lennox, R. W.; Bueding, E., The relative chemotherapeutic efficacy of a nitrovinylfuran (SQ 18,506) against immature and mature stages of Schistosoma mansoni. Am J Trop Med Hyg 1972, 21 (3), 302-6.
50. Dunsford, H. A.; Keysser, C. H.; Dolan, P. M.; Seed, J. L.; Bueding, E., Carcinogenicity of the antischistosomal nitrofuran trans-5-amino-3-[2-(5-nitro-2-furyl)vinyl]-1,2,4-oxadiazole. J Natl Cancer Inst 1984, 73 (1), 151-60.
51. Kikuth, W.; Gonnert, R., Experimental studies on the therapy of schistosomiasis. Ann Trop Med Parasitol 1948, 42 (3-4), 256-67.
52. Rosi, D.; Peruzzotti, G.; Dennis, E. W.; Berberian, D. A.; Freele, H.; Archer, S., A new active metabolite of "Miracil D". Nature 1965, 208 (5014), 1005-6.
53. Rosi, D.; Merola, A. J.; Archer, S., A possible metabolic basis for the schistosomicidal activity of Mirasan and N-(3-chloro-4-methylphenyl)-piperazine. Life Sci 1967, 6 (13), 1433-7.
54. Richards, H. C.; Foster, R., A new series of 2-aminomethyltetrahydroquinoline derivatives displaying schistosomicidal activity in rodents and primates. Nature 1969, 222 (5193), 581-2.
55. Hardman, J. G. L., L.E.; Gilman, A. G, Goodman & Gilman, The Pharmacological Basis of Therapeutics. 10 ed.; McGraw-Hill Professional: 2001.
56. Bueding, E.; Fisher, J.; Bruce, J., The antischistosomal activity of a chloroindazole analog of hycanthone in mice infected with Schistosoma mansoni. J Pharmacol Exp Ther 1973, 186 (3), 402-7.
57. Soliman, R.; Mokhtar, H. M.; el Sadany, S. K., Synthesis of new 8-(5-substituted amino-1,3,4-oxadiazol-2-yl) and 8-(5-substituted amino-1,3,4-thiadiazol-2-yl) methoxyquinolines with antibilharzial activity. J Pharm Sci 1984, 73 (3), 403-5.
58. el-Hamouly, W.; Pica-Mattoccia, L.; Cioli, D.; Schwartz, H. M.; Archer, S., Studies on some derivatives of oxamniquine. J Med Chem 1988, 31 (8), 1629-31.
59. Filho, S. B.; Gargioni, C.; Silva Pinto, P. L.; Chiodelli, S. G.; Gurgel Vellosa, S. A.; da Silva, R. M.; da Silveira, M. A., Synthesis and evaluation of new oxamniquine derivatives. Int J Pharm 2002, 233 (1-2), 35-41.
60. Seubert, J.; Pohlke, R.; Loebich, F., Synthesis and properties of Praziquantel, a novel broad spectrum anthelmintic with excellent activity against Schistosomes and Cestodes. Experientia 1977, 33 (8), 1036-7.
61. Gonnert, R.; Andrews, P., Praziquantel, a new board-spectrum antischistosomal agent. Z Parasitenkd 1977, 52 (2), 129-50.
62. Frohberg, H.; Schulze Schencking, M., Toxicological profile of praziquantel, a new drug against cestode and schistosome infections, as compared to some other schistosomicides. Arzneimittelforschung 1981, 31 (3a), 555-65.
63. Caffrey, C. R., Chemotherapy of schistosomiasis: present and future. Curr Opin Chem Biol 2007, 11 (4), 433-9.
64. Valls, N., Segarra, V.M., Lopez, X., Bosch, J., Praziquantel analogs. II. Synthesis of 4-oxooctahydropyrazino[1',2':1,2]pyrido[3,4-b]-and-[4,3-b]indoles. Heterocycles 1989, 29 (02), 231-136.
65. Abo-Ghalia, M. H.; Soliman, A. E., Synthesis and antischistosomal activity of a new 2-nicotinoyl dipeptide analogue of praziquantel. Arzneimittelforschung 1996, 46 (2), 207-9.
66. Abo-Ghalia, M. H.; Soliman, A. M., Synthesis and study of the antischistosomal potency and induced biological parameters of a new 2-palmitoyl analogue of the universal antihelminthic praziquantel. Acta Pol Pharm 2000, 57 (1), 53-9.
67. Abo-Ghalia, C. H.; Soliman, A. M., Synthetic and bioorganic investigations of 2-cyclohexylthiocarbonyl(1,2,3,6,7,11B) hexahydro-4H-pyrazino [2-1a]isoquinoline-4-thione, a new dithione mimic of the universal anthelminthic Praziquantel. Acta Pol Pharm 2001, 58 (5), 381-9.
68. Botros, S.; William, S.; Hammam, O.; Zidek, Z.; Holy, A., Activity of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine against Schistosomiasis mansoni in mice. Antimicrob Agents Chemother 2003, 47 (12), 3853-8.
69. Pax, R.; Bennett, J. L; Fetterer, R. A., Benzodiazine derivative and praziquantel: effects on musculature of Schistosoma mansoni and Schistosoma japonicum. Naunyn-Schiedbergs Arch Pharmacol 1978, 304, 309-315.
70. Becker, B.; Mehlhorn, H.; Andrews, P.; Thomas, H.; Eckert, J., Light and electron microscopic studies on the effect of praziquantel on Schistosoma mansoni, Dicrocoelium dendriticum, and Fasciola hepatica (Trematoda) in vitro. Z Parasitenkd 1980, 63, 113-128.
71. Michael, J.; Doenhoffa, D. C.; and Jurg, U., Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis 2008, 21, 659-667.
72. Jeziorski, M. C.; Greenberg, R. M., Voltage-gated calcium channel subunits from platyhelminths: potential role in praziquantel action. Int J Parasitol 2006, 36, 625-632.
73. Angelucci, F.; Basso, A.; Bellelli, A.; Brunori, M.; Pica, M. L.; Valle, C., The antischistosomal drug praziquantel is an adenosine antagonist. Parasitology 2007, 134, 1215-1221.
74. Tallima, H. E. l.; Ridi, R., Praziquantel binds Schistosoma mansoni adult worm actin. Int J Antimicrob Agents 2007, 29, 570-575.
75. Rogers, S. H.; Bueding, E., Hycanthone resistance: development in Schistosoma mansoni. Science 1971, 172 (987), 1057-8.
76. Fallon, P. G.; Doenhoff, M. J., Drug-resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific. Am J Trop Med Hyg 1994, 51 (1), 83-8.
77. Bennett, J. L.; Day, T.; Liang, F. T.; Ismail, M.; Farghaly, A., The development of resistance to anthelmintics: a perspective with an emphasis on the antischistosomal drug praziquantel. Exp Parasitol 1997, 87 (3), 260-7.
78. Andrews, P.; Thomas, H.; Pohlke, R.; Seubert, J., Praziquantel. Med Res Rev 1983, 3 (2), 147-200.
79. Ismail, M.; Metwally, A.; Farghaly, A.; Bruce, J.; Tao, L. F.; Bennett, J. L., Characterization of isolates of Schistosoma mansoni from Egyptian villagers that tolerate high doses of praziquantel. Am J Trop Med Hyg 1996, 55 (2), 214-8.
80. Ismail, M.; Botros, S.; Metwally, A.; William, S.; Farghally, A.; Tao, L. F.; Day, T. A.; Bennett, J. L., Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers. Am J Trop Med Hyg 1999, 60 (6), 932-5.
81. Liang, Y. S.; Coles, G. C.; Doenhoff, M. J.; Southgate, V. R., In vitro responses of praziquantel-resistant and-susceptible Schistosoma mansoni to praziquantel. Int J Parasitol 2001, 31 (11), 1227-35.
82. Katz, N., Dias, E.P., Araújo, N., Souza, C. P., Estudo de uma cepa humana de Shistisoma mansoni resistente a agentes esquitossomicidas. Rev Soc Bras Med Trop 1978, 7, 381-387.
83. Campos, R.; Moreira, A. A.; Sette, H., Jr.; Chamone, D. A.; Da Silva, L. C., Hycanthone resistance in a human strain of Schistosoma mansoni. Trans R Soc Trop Med Hyg 1976, 70 (3), 261-2.
84. Coles, G. C.; Mutahi, W. T.; Kinoti, G. K.; Bruce, J. I.; Katz, N., Tolerance of Kenyan Schistosoma mansoni to oxamniquine. Trans R Soc Trop Med Hyg 1987, 81 (5), 782-5.
85. Dias, L. C.; Pedro, R. J.; Rigo, E.; Goto, M. M.; Mafra, G. L., [A human strain of Schistosoma mansoni resistant to schistosomicides]. Rev Saude Publica 1978, 12 (1), 110.
86. Guimaraes, R. X.; Tchakerian, A.; Dias, L. C.; de Almeida, F. M.; Vilela, M. P.; Cabeca, M.; Takeda, A. K., [Resistance to hycanthone and oxamniquine in patients with a clinical hepatointestinal form of schistosomiasis]. AMB Rev Assoc Med Bras 1979, 25 (2), 48-50.
87. Yeang, F. S.; Marshall, I.; Huggins, M., Oxamniquine resistance in Schistosoma mansoni: fact or fiction? Ann Trop Med Parasitol 1987, 81 (3), 337-9.
88. Cioli, D.; Pica-Mattoccia, L.; Archer, S., Resistance of schistosomes to hycanthone and oxamniquine. Mem Inst Oswaldo Cruz 1989, 84 Suppl 1, 38-45.
89. Drescher, K. M.; Rogers, E. J.; Bruce, J. I.; Katz, N.; Dias, L. C.; Coles, G. C., Response of drug resistant isolates of Schistosoma mansoni to antischistosomal agents. Mem Inst Oswaldo Cruz 1993, 88 (1), 89-95.
90. Gryseels, B.; Stelma, F. F.; Talla, I.; van Dam, G. J.; Polman, K.; Sow, S.; Diaw, M.; Sturrock, R. F.; Doehring-Schwerdtfeger, E.; Kardorff, R.; et al., Epidemiology, immunology and chemotherapy of Schistosoma mansoni infections in a recently exposed community in Senegal. Trop Geogr Med 1994, 46 (4), 209-19.
91. Stelma, F. F.; Talla, I.; Sow, S.; Kongs, A.; Niang, M.; Polman, K.; Deelder, A. M.; Gryseels, B., Efficacy and side effects of praziquantel in an epidemic focus of Schistosoma mansoni. Am J Trop Med Hyg 1995, 53 (2), 167-70.
92. Cioli, D., Praziquantel: is there real resistance and are there alternatives? Curr Opin Infect Dis 2000, 13 (6), 659-663.
93. Gryseels, B.; Mbaye, A.; De Vlas, S. J.; Stelma, F. F.; Guisse, F.; Van Lieshout, L.; Faye, D.; Diop, M.; Ly, A.; Tchuem-Tchuente, L. A.; Engels, D.; Polman, K., Are poor responses to praziquantel for the treatment of Schistosoma mansoni infections in Senegal due to resistance? An overview of the evidence. Trop Med Int Health 2001, 6 (11), 864-73.
94. Guisse, F.; Polman, K.; Stelma, F. F.; Mbaye, A.; Talla, I.; Niang, M.; Deelder, A. M.; Ndir, O.; Gryseels, B., Therapeutic evaluation of two different dose regimens of praziquantel in a recent Schistosoma mansoni focus in Northern Senegal. Am J Trop Med Hyg 1997, 56 (5), 511-4.
95. Stelma, F. F.; Sall, S.; Daff, B.; Sow, S.; Niang, M.; Gryseels, B., Oxamniquine cures Schistosoma mansoni infection in a focus in which cure rates with praziquantel are unusually low. J Infect Dis 1997, 176 (1), 304-7.
96. Trouiller, P & Olliaro P., Drug development output during 1975-96: what proportion for tropical diseases? Int J Infect Dis 1999 3, 61-63.
97. Hudson, A.; Randall, A.; Ginger, W.; Ginger, C. D.; Hill, B.; Latter, V. S.; McHardy, N.; Williams R B., Novel antimalarial hydroxynaphthoquinone with potent broad anti-protozoal activity Parasitology 1985, 90, 45-55.
98. Hans Veeken and Bernard Pécoul Drugs for 'neglected diseases': a bitter pill. Trop Med Int Health 2000, 5(5), 309-311.
99. Monzote, L., A review of anti-parasitic patents (1988-2008). Recent Pat Antiinfect Drug Discov 2008, 3 (3), 177-91.
100. McManus, D. P.; Loukas, A., Current status of vaccines for schistosomiasis. Clin Microbiol Rev 2008, 21 (1), 225-42.
101. Kuntz, A. N.; Davioud-Charvet, E.; Sayed, A. A.; Califf, L. L.; Dessolin, J.; Arnér, E. S.; Williams, D. L., Thioredoxin glutathione reductase from Schistosoma mansoni: an essential parasite enzyme and a key drug target. PloS Med 2007, 4, e206.
102. Sayed, A. A.; Simeonov, A.; Thomas, C. J.; Inglese, J.; Austin, C. P.; Williams, D. L., Identification of oxadiazoles as new drug leads for the control of schistosomiasis. Nat Med 2008, 14, 407-412.
103. Cioli, D.; Valle, C.; Angelucci, F.; Miele, A. E., Will new antischistosomal drugs finally emerge? Trends Parasitol 2008, 24, 379-382.
104. Sayed, A. A.; Cook, S. K.; Williams, D. L., Redox balance mechanisms in Schistosoma mansoni rely on peroxiredoxins and albumin and implicate peroxiredoxins as novel drug targets. J. Biol. Chem 2006, 281(25), 17001-17010.
105. Kwatia, M. A.; Botkin, D. J.; Williams, D. L., Molecular and enzymatic characterization of Schistosoma mansoni thioredoxin peroxidase. J. Parasitol 2000, 86, 908-915.
106. Sayed, A. A.; Williams, D.L. Biochemical characterization of 2-Cys peroxiredoxins from Schistosoma mansoni. J. Biol. Chem., 2004, 279, 26159-26166.
107. Abdulla, M. H.; Lim, K. C.; Sajid, M.; McKerrow, J. H.; Caffrey, C. R., Schistosomiasis mansoni: novel chemotherapy using a cysteine protease inhibitor. PloS Med 2007, 4, e14.
108. Morales, M. E.; Rinaldi, G.; Gobert, G. N.; Kines, K.J.; Tort, J. F.; Brindley, P. J., RNA interference of Schistosoma mansoni cathepsin D, the apical enzyme of the hemoglobin proteolysis cascade. Mol. Biochem. Parasitol 2008, 157(2), 160-168.
109. Ovat, A.; Muindi, F.; Fagan, C.; Brouner, M.; Hansell, E.; Dvorák, J.; Sojka, D.; Kopácek, P.; McKerrow, J. H.; Caffrey, C. R.; Powers, J. C,. Aza-peptidyl Michael acceptor and epoxide inhibitors-potent and selective inhibitors of Schistosoma mansoni and Ixodes ricinus legumains (asparaginyl endopeptidases). J. Med. Chem 2009, 52(22), 7192-7210.
110. Francesco, A.; Adriana, E. M.; Giovanna, B.; Maurizio, B.; Daniela, D.; Andrea, B., Macromolecular Bases of Antischistosomal Therapy. Curr Top Med Chem 2011, 11, 2012-2028.
111. Senft, A. W.; Miech, R. P.; Brown, P. R.; Senft, D. G., Purine metabolism in Schistosoma mansoni. Int. J. Parasitol 1972, 2, 249-260.
112. Pereira, H. M.; Berdini, V.; Ferri, M. R.; Cleasby, A.; Garratt, R. C.; Crystal structure of Schistosoma purine nucleoside phosphorylase complexed with a novel monocyclic inhibitor. Acta Trop 2010, 114(2), 97-102.
113. Castilho, M. S.; Postigo, M. P.; Pereira, H. M.; Oliva, G.; Andricopulo, A. D., Structural basis for selective inhibition of purine nucleoside phosphorylase from Schistosoma mansoni: kinetic and structural studies. Bioorg. Med. Chem 2010, 18(4), 1421-1427.
114. Fenwick, A.; Webster, J. P., Schistosomiasis: challenges for control, treatment and drug resistance. Curr Opin Infect Dis 2006, 19 (6), 577-82.
115. Verjovski-Almeida, S.; DeMarco R., Martins, E. A.; Guimarães, P. E.; Ojopi, E. P.; Paquola, A. C.; Piazza, J. P.; Nishiyama, M. Y.; Kitajima, J. P.; Adamson, R. E.; Ashton, P. D.; Bonaldo, M. F.; Coulson, P. S.; Dillon, G. P.; Farias, L. P.; Gregorio, S. P.; Ho, P. L.; Leite, R. A.; Malaquias, L. C.; Marques, R. C.; Miyasato, P. A.; Nascimento, A. L.; Ohlweiler, F. P.; Reis, E. M.; Ribeiro, M. A.;, Sá, R. G.; Stukart, G. C.; Soares, M. B.; Gargioni, C.; Kawano, T.; Rodrigues, V.; Madeira, A. M.; Wilson, R. A.; Menck, C. F.; Setubal, J. C.; Leite, L. C.; Dias-Neto, E., Transcriptome analysis of the acoelomate human parasite Schistosoma mansoni. Nat Genet 2003, 35(2), 148-57.